Best Healthcare Companies in Osaka, Japan
The 57 best Healthcare companies in Osaka, Japan in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Kringle Pharma.
Ranked: Best Healthcare companies in Osaka
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Kringle Pharma Developer of recombinant protein drugs for neuro, renal and oncology disorders | $32M | 75 mo ago | Public | — | 2001 | BootstrapNginxjQuery+3 | 135 patents Neuroregenerative biologic therapies for acute/subacute spinal cord injury, including HGF production | — |
| 2 | AXM Pharma National acquirer of wireless communication towers | $16M | 227 mo ago | Public | Wang Wei Shi CEO & Chairman | 1999 | — | — | — |
| 3 | HOIST Provider of drugs development services | $5M | 38 mo ago | Seed | — | 2019 | — | — | — |
| 4 | eWeLL Co Provider of electronic medical record services | $4M | 109 mo ago | Acquired | — | 2012 | ZohoApache HTTP ServerAmazon Web Services+11 | — | — |
| 5 | ALTURA X Provider of talent & learning management and IT services for health care sector | $2M | 27 mo ago | Series A | Eito Sasakura CEO | 2016 | STUDIOFirebaseNode.js+11 | — | — |
| 6 | Periotherapia Periotherapia is a drug discovery business with triple negative breast cancer as the first indication. | $648K | 17 mo ago | Seed | Yoshiaki Taniyama Founder | 2017 | WordPressMySQLPHP+13 | 9 patents Therapeutic antibody fragments and engineered protein therapeutics | — |
| 7 | HANOWA Provider of dental care platform and recruitment services | $551K | 62 mo ago | Seed | Arai Shohei CEO | 2019 | WordPressMySQLPHP+35 | — | — |
| 8 | DLeader Developer of an AI platform streamlining drug discovery and development | $120K | 10 mo ago | Seed | Qingwen Chen Co-Founder & CEO | 2024 | — | — | — |
Top 12 Healthcare companies in Osaka
#1
Seed · Osaka, Osaka · founded 2024$120Kraised▾
Developer of an AI platform streamlining drug discovery and development. The platform integrates machine learning and computational modeling to accelerate therapeutic development. It leverages deep learning and generative models to transform the drug discovery pipeline. The platform supports target identification, molecular design, and preclinical evaluation. It uncovers novel therapeutics with greater speed, precision, and scalability.
- Aug 2025Seed$120K
#2
Seed · Osaka, Osaka · founded 2017 · 8 employees$647.7Kraised▾
Developer of medical treatments designed to tackle intractable diseases. The company's therapies construct a pipeline that makes use of disease-specific antibodies and contributes to early diagnosis and precision medicine using companion diagnostics, enabling health professionals to discover new drugs for breast cancers, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy.
- Jan 2025Conventional Debt—
- Jan 2025Seed$647.7K
#3
Series A · Osaka, Osaka · founded 2016 · 5 employees$2Mraised▾
Developer of a talent management and educational media platform intended to assist medical professionals. The company's platform offers assistance to organizational management of hospitals and long-term care facilities that are prone to the deficit, cloud personnel service specializing in medical care, enabling healthcare workers to assist patients and improve their quality of life.
- Mar 2024Series A$2M
#4
Seed · Osaka, Osaka · founded 2019 · 4 employees$5.4Mraised▾
Operator of a medical research and development company intended to discover and develop cancer treatment drugs. The company's research uses technology to provide information and realize the future of innovative cancer therapeutic drugs and healthy longevity, enabling clinicians to treat patients without hassle.
- Apr 2023Seed$2.2M
- 2022Seed$868.8K
- 2020Seed$1.4M
- Nov 2019Seed$923.1K
#5
Public · Ibaraki, Osaka · founded 2001 · 12 employees$32.1Mraised▾
Kringle Pharma, a spin-off from the Osaka University, is developing recombinant protein drugs for treating neuro, renal and oncology disorders. The company has developed NK4 (intramolecular fragment) with antagonist activity towards hepatocyte growth factor (HGF) which has a role in the regeneration and repair of various tissues and organs. The company developed and has cleared phase I trials of recombinant human HGF (KP-100IT) against ALS, along with the phase I/II trials for acute spinal cord injury and US phase 1 trial for acute kidney injury have been completed.
- Apr 2020Series B$15.5M
- Dec 2016Series A$5.4M
- Mar 2008Series A$1.6M
- Dec 2007Series A$9.6M
#6
Public · Osaka, Osaka · founded 1999$16.4Mraised▾
National acquirer of wireless communication towers. This company purchases tower assets from sellers, handling all future maintenance and upkeep costs. Sellers retain tower use at no cost. For developers, the company funds all development and construction, offering flexible compensation structures including lump-sum payments, leasing commissions, and earn-outs.
- Aug 2007Post IPO$200K
- Apr 2006Conventional Debt$375K
- May 2005Conventional Debt$3.4M
- Jun 2004Post IPO$5M
#7
Acquired · Osaka, Osaka · founded 2012 · 61 employees$4.1Mraised▾
Provider of electronic medical record services
- Jun 2017Series A$4.1M
#8
Seed · Osaka, Osaka · founded 2019$551.3Kraised▾
Provider of dental care platform and recruitment services. It is a matching platform between freelance dental hygienists and dental clinics.
- Apr 2021Seed$551.3K
#9
Late Stage · Osaka, Osaka · founded 2004—raised▾
Operator of second-hand goods designed to sell, purchase and exhibit reusable items. The company engages in the recycling of used items, thereby helping customers by acting as a bridge to resell used goods and items at affordable prices.
- Jan 2023PE—
#10
Deadpooled · Osaka, Osaka · founded 2015 · 5 employees—raised▾
Epigeneron is a drug discovery service provider for epigenetic and anti-microbial drugs. They use their proprietary drug discovery target identification system. Also, they are offering epigenetic drug targets for treating intractable diseases like cancer, Central Nervous System, dementia, metabolic diseases, and infectious diseases.
- Mar 2018Seed—
#11
Deadpooled · Osaka, Osaka · founded 2006—raised▾
Genomix is a research-stage biotech company focused on developing small molecules that can induce tissue repair and regeneration in vivo. The company was founded as a spinoff from the Osaka University's Graduate School of Medicine to commercially develop a bone marrow pluripotent stem cell mobilization factor identified by Professor Katsuhito Tamai.
- 2017PE—
- Jan 2015PE—
#12
Acquired · Osaka, Osaka · founded 2000—raised▾
Developer of information technology assets intelligence software tools. The company provides a software that helps the users to create real assets comprising source code and heterogeneous objects.
- Jun 2013Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Healthcare coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.